modelN03AF02
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Oxcarbazepine | |
| ATC code: | N03AF02 | route: | oral |
| compartments: | 1 | |
| dosage: | 600 | mg |
| volume of distribution: | 49 | L |
| clearance: | 2.1 | L/h |
| other parameters in model implementation | ||
Oxcarbazepine is an antiepileptic drug approved for the treatment of partial seizures in adults and children. It is a structural derivative of carbamazepine and is used as monotherapy or adjunctive therapy in epilepsy. It is currently approved and widely used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.
References
Yang, Q, et al., & Li, X (2023). Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients. European journal of hospital pharmacy : science and practice 30(e1) e90–e96. DOI:10.1136/ejhpharm-2022-003357 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35787526
Li, S, et al., & Liu, Z (2024). Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real-world study. Epilepsia 65(6) 1687–1697. DOI:10.1111/epi.17954 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38572689
Lin, WW, et al., & Wang, CL (2019). Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. European journal of clinical pharmacology 75(3) 381–392. DOI:10.1007/s00228-018-2600-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30456415
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)